Articles related to ALZHEIMER'S/DEMENTIA

The findings supported the National Institute on Aging-Alzheimer’s Association (NIA-AA) research framework for Alzheimer’s disease, which is based on biomarkers of amyloid, tau, and neurodegeneration.

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.

Scientists have started questioning the veracity of images accompanying University of Minnesota Sylvain Lesné, PhD’s studies touting major breakthroughs. Lesné’s images had supported a theory that oligomer species Aβ*56 was the most important of many oligomers thought to be more pathogenic than other plaques — and thus, a potential drug target.

Higher levels of physical activity were associated with greater processing speed reserve in older women but not in older men, according to a recent study. This is good news, as dementia may be slowed by cognitive reserve, the capacity to maintain cognition in the face of brain damage. A cognitively active lifestyle that includes reading and information processing may delay the onset of dementia in Alzheimer’s disease by up to 5 years in persons in their 80s, according to recent research. Other research has suggested that cognitive reserve may be one factor in some centenarians’ ability to resist cognitive decline in the face of brain dysfunction.

The first in a two-part series, this 0.50-credit, 30-minute CME multiplatform program discusses the importance of early identification of AD and how to detect it early, the pathobiology of AD and potential treatments in development to target this pathology, and current treatment options, including the appropriate use of anti-amyloid monoclonal antibody (mAb) treatment.

As this review discovered, repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. Still, the report offers several factors that should be considered before designing future clinical trials.